18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Global industry news
Merck KGaA antes up €250M to bridge R&D with manufacturing
FDA faults Biocon's biosimilars plant during preapproval review
Eli Lilly, Incyte's Olumiant notches another atopic dermatitis win. But can it fight Dupixent?
+7 495 442 37 85
+7 985 908 58 18
Registration of Medical Drugs in Russia
Registration of Pharmaceuticals in Russia
Registration of Pharmaceutical Dossier Variations in Russia
Registration of Pharmaceuticals in CIS
Clinical Studies in Russia
Clinical Studies for Registration of Pharmaceuticals in Russia
International Phase III Clinical Studies
Phase I, Phase II (IIa, IIb) Clinical Studies
Preclinical Studies in Russia
Preclinical Studies for Registration of Pharmaceuticals in Russia
Preclinical Studies for Registration of Biopharmaceuticals in Russia
In Vitro Preclinical Studies in Russia
Regulatory Consulting in Russia and EEU
Certification of Medical Drugs and Medical Devices in Russia
Registration of Medical Devices in Russia
Russian GMP inspection of pharmaceutical manufacturers
Regulatory Events Russia
Russian Regulatory News
You are here:
Pharegis LLC / ООО "Фареджис"
3-1 Begovaya str. ("NordStar Tower", 31st flr), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
TAX ID (TIN): 7718278100
+7 495 442 37 85 9am-6pm GMT+3
+ 7 495 442 37 85
+ 7 985 908 58 18
Send an Email
Send a copy to yourself
SHARE THIS BY:
Create an account
Forgot your username?
Forgot your password?
Drugs.com - New Drug Approvals
FDA Approves Tazverik (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma
FDA Approves Tepezza (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)
FDA Approves Ozempic (semaglutide) for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes and Known Heart Disease
FDA Approves Numbrino (cocaine hydrochloride) Nasal Solution for Nasal Anesthesia
FDA Approves Valtoco (diazepam nasal spray) as a Seizure Rescue Treatment
News and press releases
Martina Schüssler-Lenz re-elected as chair of Committee for Advanced Therapies, , 24/01/2020
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 21-23 January 2020, CVMP, 24/01/2020
Court of Justice upholds EMA’s approach to transparency, , 22/01/2020
Ten recommendations to unlock the potential of big data for public health in the EU, , 20/01/2020
Drugs.com - Clinical Trials
Rafael Pharmaceuticals Announces the Initiation of a Phase 1b/2 Clinical Trial of CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
Cranbury, NJ, Jan. 21, 2020...
BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysi
Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection
WHITE PLAINS, N.Y., Jan. 15,...
Kala Pharmaceuticals Announces Completion of Enrollment of STRIDE 3 Trial for Eysuvis (KPI-121 0.25%) for Dry Eye Disease
PharmaTimes: PharmaTimes Website RSS
NICE rejections continue, hitting Novo’s Saxenda next
NIHR to invest £59m in AMR, air pollution and infectious diseases
EU expands Stelara indication following NICE rejection
Havas Lynx bags seven Golds at PM Society Awards
75% drop in cases from UK meningitis B vaccine
Terms of Service
Sample Non-Disclosure Agreement